CETIRIZINE HYDROCHLORIDE HIVES RELIEF Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cetirizine Hydrochloride Hives Relief, and what generic alternatives are available?
Cetirizine Hydrochloride Hives Relief is a drug marketed by Aurobindo Pharma Ltd, Bionpharma, Sun Pharm Inds Inc, Amneal Pharms Ny, Taro, and Torrent Pharms Llc. and is included in seven NDAs.
The generic ingredient in CETIRIZINE HYDROCHLORIDE HIVES RELIEF is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-eight suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetirizine Hydrochloride Hives Relief
A generic version of CETIRIZINE HYDROCHLORIDE HIVES RELIEF was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CETIRIZINE HYDROCHLORIDE HIVES RELIEF?
- What are the global sales for CETIRIZINE HYDROCHLORIDE HIVES RELIEF?
- What is Average Wholesale Price for CETIRIZINE HYDROCHLORIDE HIVES RELIEF?
Summary for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 27 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 91 |
Patent Applications: | 2,616 |
DailyMed Link: | CETIRIZINE HYDROCHLORIDE HIVES RELIEF at DailyMed |
Recent Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
CURE Drug Repurposing Collaboratory (CDRC) | Phase 3 |
Emory University | Phase 3 |
Ruijin Hospital | Phase 1/Phase 2 |
See all CETIRIZINE HYDROCHLORIDE HIVES RELIEF clinical trials
Pharmacology for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Drug Class | Histamine-1 Receptor Antagonist |
Mechanism of Action | Histamine H1 Receptor Antagonists |